Joanne J van der Vis
Overview
Explore the profile of Joanne J van der Vis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
543
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Plante-Bordeneuve T, Terwiel M, van der Vis J, van Es W, Veltkamp M, Grutters J, et al.
ERJ Open Res
. 2025 Feb;
11(1).
PMID: 40008166
https://bit.ly/40KC7Cr.
2.
Manali E, Griese M, Nathan N, Uzunhan Y, Borie R, Michel K, et al.
Eur Respir J
. 2024 Dec;
65(2).
PMID: 39638417
Background: Interstitial lung disease is rarer in children than adults, but, with increasing diagnostic awareness, more cases are being discovered. The prognosis of childhood interstitial lung disease is often poor,...
3.
Bloem A, Dolk H, Wind A, van der Vis J, Kampen M, Custers J, et al.
Respir Med
. 2024 Nov;
236:107862.
PMID: 39571824
Introduction: Idiopathic pulmonary fibrosis (IPF) is a fatal progressive fibrosing lung disease. A decreased 6-min walk distance (6MWD) and exercise-induced oxygen desaturation measured during the 6-min walk test (6MWT), are...
4.
Juge P, Sparks J, Gazal S, Ebstein E, Borie R, Debray M, et al.
Rheumatol Adv Pract
. 2024 Jun;
8(2):rkae059.
PMID: 38854416
Objective: Recently, a genome-wide association study identified an association between RA-associated interstitial lung disease (ILD) and rs12702634 in the Japanese population, especially for patients with a usual interstitial pneumonia (UIP)...
5.
Groen K, van der Vis J, van Batenburg A, Kazemier K, de Bruijn M, Stadhouders R, et al.
ERJ Open Res
. 2024 Feb;
10(1).
PMID: 38375433
Introduction: Pulmonary fibrosis is a severe disease which can be familial. A genetic cause can only be found in ∼40% of families. Searching for shared novel genetic variants may aid...
6.
Klay D, Kazemier K, van der Vis J, Smits H, Grutters J, van Moorsel C
Int J Mol Sci
. 2023 Dec;
24(23).
PMID: 38069069
In sporadic idiopathic pulmonary fibrosis (sIPF) and pulmonary fibrosis caused by a mutation in telomere (TRG-PF) or surfactant related genes (SRG-PF), there are a number of aberrant cellular processes known...
7.
Hoffman T, van Moorsel C, van der Vis J, Biesma D, Grutters J
ERJ Open Res
. 2023 Sep;
9(5).
PMID: 37753281
Background: Telomere dysfunction can underly the development of idiopathic pulmonary fibrosis (IPF), and recent work suggests that patients with telomere syndromes might benefit from treatment with androgens, such as danazol....
8.
Kraaijvanger R, Ambarus C, Damen J, van der Vis J, Kazemier K, Grutters J, et al.
Int J Mol Sci
. 2023 Aug;
24(16).
PMID: 37628972
The unknown etiology of sarcoidosis, along with the variability in organ involvement and disease course, complicates the effective treatment of this disease. Based on recent studies, the cellular inflammatory pathways...
9.
Platenburg M, van Moorsel C, Wiertz I, van der Vis J, Vorselaars A, Veltkamp M, et al.
Lung
. 2023 Jun;
201(4):335-343.
PMID: 37341844
Purpose: Pirfenidone and nintedanib unequivocally inhibit FVC decline, but have been inconsistently linked to reduced mortality in phase III studies. On the contrary, real-world data show a survival benefit of...
10.
Platenburg M, van der Vis J, Grutters J, van Moorsel C
Medicina (Kaunas)
. 2023 Feb;
59(2).
PMID: 36837496
Progressive pulmonary fibrosis (PPF) is a recently described term reserved for patients with fibrotic ILD other than idiopathic pulmonary fibrosis (IPF) with fast clinical deterioration. Here, survival and prognostic biomarkers...